Antara News·Indonesia·Saturday, September 5, 2026 at 11:47 AM

BPOM invites pharmaceutical industry to bolster clinical trials

Translate

Asep Firmansyah, Raka Adji

Jakarta (ANTARA) - The Food and Drug Monitoring Agency (BPOM) called on domestic and foreign pharmaceutical firms to collaborate in developing a clinical trial ecosystem to strengthen Indonesia's self-reliance in medicines and medical devices.

"Clinical trials aren't cheap, they're expensive. That is why we are facilitating pharmaceutical companies, both local and international, to join and expand their operations in Indonesia," BPOM Head Taruna Ikrar said in Jakarta on Saturday.

Speaking at the 2026 Annual Meeting of the Indonesian Association for the Study of Medicinals (IASMED), Ikrar noted Indonesia possesses the resources to support clinical trials, ranging from facilities to a diverse range of research cases.

He highlighted clinical trials are a critical phase in developing health products before they can be used in patient treatment.

He assessed the 2026 IASMED Annual Meeting was a strategic forum for regulators, academics, hospitals, pharmaceutical companies, contract research organizations (CROs), and clinical trial professionals to bolster collaboration and advance Indonesia's clinical trial ecosystem.

In boosting the clinical trial development in Indonesia, Ikrar pointed out three priorities. First, building an integrated ecosystem that involves BPOM, the Ministry of Health, hospitals, and various healthcare and research facilities.

"On our end, we are also drafting regulations to create an environment that supports clinical trials to thrive," he said.

Second, advancing scientific knowledge and building the capacity of clinical trial practitioners. It includes determining which products to test, ensuring facility readiness, and enforcing ethical guidelines and operational standards.

Ikrar affirmed the BPOM and the Ministry of Health are committed to supporting improvements in those areas to realise stronger clinical trial execution in Indonesia.

Third, reinforcing industrial support, given that running clinical trials requires significant financial investment.

Active industry participation is therefore deemed essential to expanding capacity and ensuring the sustainability of clinical research in Indonesia.

IASMED President Endang Hoyaranda affirmed the organisation's commitment to maintaining the momentum built through cross-sector collaboration and capacity building for clinical trial professionals in Indonesia.

She expressed optimism that stronger collaboration among the government, regulators, academics, healthcare facilities, and the industry will attract more global clinical trial investments and fast-track public access to innovative treatments, vaccines, and health technologies, supporting the Golden Indonesia 2045 vision.

View the original on Antara News →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.